Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
30
01
2024
accepted:
22
03
2024
revised:
20
03
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
epublish
Résumé
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC. The incidence of severe infections was higher with BsAb (40%) than CAR-T (26%) or ADC (8%), including grade 5 infections (7% vs 0% vs 0%, respectively). Comparing T-cell redirecting therapies, the incidence rate of severe infections was significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P = 0.004). During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb. In conclusion, we observed an overall higher and more persistent risk of severe infections with BsAb. Our results also suggest a higher infection risk during periods of hypogammaglobulinemia with BsAb, and with neutropenia in CAR-T recipients.
Identifiants
pubmed: 38821925
doi: 10.1038/s41408-024-01043-5
pii: 10.1038/s41408-024-01043-5
doi:
Substances chimiques
B-Cell Maturation Antigen
0
TNFRSF17 protein, human
0
Antibodies, Bispecific
0
Immunoconjugates
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–94.
doi: 10.1182/blood-2003-06-2043
pubmed: 14512299
Nath K, Mailankody S, Usmani SZ. The role of chimeric antigen receptor T-Cell therapy in the era of bispecific antibodies. Hematol/Oncol Clin. 2023;37:1201–14.
doi: 10.1016/j.hoc.2023.05.011
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022;41:JCO.22.00842.
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705–16.
doi: 10.1056/NEJMoa2024850
pubmed: 33626253
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505.
doi: 10.1056/NEJMoa2203478
pubmed: 35661166
pmcid: 10587778
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl J Med. 2022;387:2232–44.
doi: 10.1056/NEJMoa2204591
pubmed: 36507686
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259–67.
doi: 10.1038/s41591-023-02528-9
pubmed: 37582952
pmcid: 10504075
Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023;13:34.
doi: 10.1038/s41408-023-00808-8
pubmed: 36894539
pmcid: 9998258
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26.
doi: 10.1200/JCO.2005.03.2086
pubmed: 16275935
Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al. Risk of Infections in multiple myeloma in the era of novel agents, a population-based study based on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Blood. 2023;142:4696.
doi: 10.1182/blood-2023-174228
Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D’Souza A, et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022;6:2466–70.
doi: 10.1182/bloodadvances.2021006178
pubmed: 34933344
pmcid: 9043928
Popat R, Cheok K, Sridhar A, Feely C, Mactier C, McMillan A, et al. Infection risk and use of prophylaxis with Anti-BCMA Bispecific T cell engagers and belantamab mafodotin for patients with relapsed and refractory multiple myeloma. Blood. 2023;142:4702.
doi: 10.1182/blood-2023-182725
Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26:1541–54.
doi: 10.1158/1078-0432.CCR-19-2111
pubmed: 31672768
Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021;5:5290–9.
doi: 10.1182/bloodadvances.2021004603
pubmed: 34587230
pmcid: 9153033
Kambhampati S, Sheng Y, Huang C-Y, Bylsma S, Lo M, Kennedy V, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6:2045–54.
doi: 10.1182/bloodadvances.2020004079
pubmed: 34543400
pmcid: 9006279
Cellerin E, Jourdes A, Brousse X, Vallet N, Cartau T, Denis B, et al. Cumulative incidence and characteristics of infections requiring treatment, delay in treatment administration or hospitalisation in patients with relapsed or refractory multiple myeloma treated with anti BCMA or Anti GPRC5D bispecific antibodies. Blood. 2023;142:1005.
doi: 10.1182/blood-2023-175004
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, et al. Impact of bridging chemotherapy on clinical outcomes of CD19-Specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia. Transpl Cell Ther. 2022;28:72.e1–8.
doi: 10.1016/j.jtct.2021.11.014
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with Anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4:440–51.
doi: 10.1158/2643-3230.BCD-23-0049
pubmed: 37769148
pmcid: 10618720
Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.
doi: 10.1038/s41408-023-00879-7
pubmed: 37528088
pmcid: 10394080
Mohan M, Shah N, Luan D, Monge J, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood. 2023;142:545.
doi: 10.1182/blood-2023-174875
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865–77.
doi: 10.1182/blood.2023020578
pubmed: 37300386
Thibaud S, Mia MB, Van Oekelen O, Mouhieddine TH, Schaniel C, Ghodke-Puranik Y, et al. Comprehensive characterization of prolonged unexplained cytopenias in relapsed/refractory multiple myeloma patients following BCMA-Directed CAR-T Cell Therapy. Blood. 2022;140:614–6.
doi: 10.1182/blood-2022-165646
Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.
doi: 10.1186/s13045-023-01465-x
pubmed: 37525244
pmcid: 10391746
Howard AJ, Shekarkhand T, Hamadeh IS, Wang A, Patel D, Tan C, et al. Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2023;142:3707.
doi: 10.1182/blood-2023-187889
Martín-Sánchez E, Guerrero C, Tamariz-Amador L-E, Zherniakova A, Zabaleta A, Maia C, et al. Deep characterization of immune dysfunction in patients with Multiple Myeloma (MM) and identification of cellular biomarkers for tailored vaccination strategies. Blood. 2023;142:643.
doi: 10.1182/blood-2023-181747
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B. et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023;109:906–14.
doi: 10.3324/haematol.2023.283590
pmcid: 10905074
Lesokhin AM, Richter J, Trudel S, Cohen AD, Spencer A, Forsberg PA, et al. Enduring responses after 1-Year, fixed-duration Cevostamab therapy in patients with relapsed/refractory multiple myeloma: early experience from a Phase I Study. Blood. 2022;140:4415–7.
doi: 10.1182/blood-2022-157547
Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898–903.
doi: 10.1182/bloodadvances.2023010539
pubmed: 37467036
pmcid: 10558589